Navigation Links
Genetic testing not cost-effective in guiding initial dosing of common blood thinner
Date:1/19/2009

CINCINNATINew analyses led by the University of Cincinnati (UC) show that genetic testing used to guide initial dosing of the blood-thinner warfarin may not be cost-effective for typical patients with atrial fibrillation but may be for patients at higher risk for major bleeding.

This study is being published in the Jan. 20, 2009, edition of Annals of Internal Medicine.

Warfarin is commonly prescribed to prevent blood clotting, particularly for patients with atrial fibrillationa type of abnormal heart rhythm.

Mark Eckman, MD, professor of medicine at UC and lead investigator of the study, says the U.S. Food and Drug Administration changed the labeling for warfarin in 2007, suggesting that clinicians consider genetic testing before initiating therapy.

"There are certain genes that are known to contribute to an increased sensitivity to warfarin," he says. "The idea behind genetic testingalso known as pharmacogenetic-guided dosing is to help guide the initial, and possibly lower, dose of warfarin for patients found to possess certain variants of the genes cytochrome P450 CYP2C9 and vitamin K epoxide reductase, or VKORC1. The hope is that more accurate dosing will translate into decreased major bleeds during the initiation phase of warfarin dosing, which is the first month or so."

Eckman says the study looked at whether the benefit of testing is worth the costs associated with it.

Researchers first performed an analysis combining the results of the only three clinical studies published to date to determine the degree to which pharmacogenetic-guided dosing decreases the risk of major bleeds when compared with standard induction of treatment with warfarin.

The team next constructed a model to estimate the cost-effectiveness of a genotype-guided dosing strategy.

While they found that genotype-guided dosing resulted in better outcomes, it was at a relatively high costover $170,000 per quality-adjusted life year gained.

In other analyses, where they took into consideration the limitations of the studies, researchers found that there is only a 10 percent chance that genotype-guided dosing is likely to be cost-effective.

Researchers also looked at the impact of other variables on the cost-effectiveness of genotype-guided dosing.

Eckman says results show that genotype-guided dosing might be worth the costs if it:

  • Is used for patients at high risk for hemorrhage
  • Prevents more than 32 percent of major bleeding events
  • Is available within 24 hours
  • Costs less than $200

"This could be accomplished if testing were done in-house, at lower cost and without delays," he says, noting that currently in most cases these tests need to be sent to outside laboratories which can lead to delays in starting treatment and increased cost. "Furthermore, future studies, such as the recently funded National Institutes of Health COAG trial, need to examine the impact of pharmacogenetic-guided dosing on bleeding risk and monitor outcomes long enough to determine the true duration of benefit."

Eckman also suggests that rather than excluding patients at higher risk for bleeding, studies should offer enrollment if it has already been determined that these patients require warfarin.

"Personalized, predictive medicine offers great promise, but we need to carefully examine the benefits and understand the cost-effectiveness of such strategies before we spend a lot of money on very expensive tests."


'/>"/>

Contact: Katie Pence
katie.pence@uc.edu
513-558-4561
University of Cincinnati
Source:Eurekalert

Related biology news :

1. Rethinking the genetic theory of inheritance
2. Biologist enhances use of bioinformatic tools and achieves precision in genetic annotation
3. MUHC and McGill scientists explain genetic disease first discovered in Quebec 24 years ago
4. New drug holds out promise of normal diet for sufferers of devastating PKU genetic disease
5. Growth of new brain cells requires epigenetic switch
6. Studies examine genetic determinants of ADHD
7. Genetic mutation causes familial susceptibility for degenerative brain disease
8. New genetic markers for ulcerative colitis identified, researchers report in Nature Genetics
9. Genetic variation may lead to early cardiovascular disease
10. Scientists make strides toward defining genetic signature of Alzheimers disease
11. Safe new therapy for genetic heart disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2020)... ... April 30, 2020 , ... ... diseases, announced today that it had been awarded a contract from the Biomedical ... Secretary for Preparedness and Response at the U.S. Department of Health and Human ...
(Date:4/30/2020)... ... 2020 , ... Pebble Labs USA Inc. , a biotechnology company developing ... the mission of improving global food security, announced today that they have been selected ... Food- and Ag-Tech ' virtual event, a global initiative to drive innovation in feeding ...
(Date:4/30/2020)... ... April 29, 2020 , ... ... continued growth – delivering innovative solutions for a wide range of industries including ... government agencies. A month into the new decade, it was clear to company ...
Breaking Biology News(10 mins):
(Date:4/22/2020)... ... April 21, 2020 , ... Ripple Science ... Many clinical trial teams are working remotely and have paused patient visits, forcing ... researchers continue their research during this uncertain time by giving research teams free ...
(Date:4/7/2020)... ... April 06, 2020 , ... Red Nucleus, a leading provider ... announced the release of at-home virtual learning resources for all client partners. , ... safety of our employees as we continue to implement measures to safeguard the ...
(Date:4/1/2020)... ... March 31, 2020 , ... ... using its revolutionary NEXTGENPCR endpoint thermocycler and consumables that decreases PCR amplification ... samples per run, and standard, affordable laboratory equipment, a qualitative protocol was ...
(Date:3/27/2020)... ... March 25, 2020 , ... ... veterinary histopathology laboratory located centrally in the midwest for high-quality, quick-turn, board-certified ... with a highly motivated, independent, professional team that is focused on incredible ...
Breaking Biology Technology: